Current Assets
Cash, Cash Equivalents, and Marketable Securities
Moderna Cash, Cash Equivalents, and Marketable Securities increased by 175.0% to $11M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 15.4%, from $13M to $11M. Over 4 years (FY 2021 to FY 2025), Cash, Cash Equivalents, and Marketable Securities shows a downward trend with a -47.3% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
First reportedQ4 2019
Last reportedQ1 2026May 1, 2026
Metric ID:
cash_equivalents_marketable_securities_totalHistorical Data
18 periods
| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $52M | $271M | $378M | $549M | $464M | $348M | $335M | $268M | $151M | $125M | $94M | $34M | $28M | $13M | $9M | $5M | $4M | $11M |
| QoQ Change | — | +421.2% | +39.5% | +45.2% | -15.5% | -25.0% | -3.7% | -20.0% | -43.7% | -17.2% | -24.8% | -63.8% | -17.6% | -53.6% | -30.8% | -44.4% | -20.0% | +175.0% |
| YoY Change | — | — | — | — | +792.3% | +28.4% | -11.4% | -51.2% | -67.5% | -64.1% | -71.9% | -87.3% | -81.5% | -89.6% | -90.4% | -85.3% | -85.7% | -15.4% |
Range$4M – $549M
CAGR-30.6%
Avg YoY Growth+1.4%
Median YoY Growth-69.7%
Cash, Cash Equivalents, and Marketable Securities at Other Companies
Frequently Asked Questions
- What is Moderna's cash, cash equivalents, and marketable securities?
- Moderna (MRNA) reported cash, cash equivalents, and marketable securities of $11M in Q1 2026.
- How has Moderna's cash, cash equivalents, and marketable securities changed year-over-year?
- Moderna's cash, cash equivalents, and marketable securities decreased by 15.4% year-over-year, from $13M to $11M.
- What is the long-term trend for Moderna's cash, cash equivalents, and marketable securities?
- Over 4 years (2021 to 2025), Moderna's cash, cash equivalents, and marketable securities has grown at a -47.3% compound annual growth rate (CAGR), from $52M to $4M.